Latest Clinical Trials News

Page 14 of 140
Cleo Diagnostics has appointed Bio-Techne’s CLIA-certified U.S. laboratory Asuragen to run pivotal clinical validation for its pre-surgical ovarian cancer test. The approximately 1,470-sample program is intended to generate the evidence supporting a planned FDA 510(k) submission in the first half of calendar 2027.
Ada Torres
Ada Torres
10 Sept 2026
A multimillion-dollar, multiyear NIH grant will fund an expanded access program for Neurizon’s investigational NUZ-001, potentially giving up to 200 US patients access to the therapy for as long as 96 weeks. The program is designed to add long-term safety, survival and biomarker data alongside the pivotal HEALEY ALS trial.
Ada Torres
Ada Torres
9 Sept 2026
Prescient Therapeutics has given shareholders another week to participate in its A$7 million share purchase plan, citing delayed documentation and requests for more time. The capital raising is intended to fund PTX-100 through a planned December 2026 Dose Optimisation Committee meeting.
Ada Torres
Ada Torres
8 Sept 2026
Neurizon has appointed Dr Chris Bremer as chief executive as its NUZ-001 ALS program moves towards topline Phase 2/3 results expected in late Q2 2027. The incoming CEO brings more than 20 years of pharmaceutical and biotechnology experience, including over US$1 billion in licensing transactions.
Ada Torres
Ada Torres
7 Sept 2026
Arovella Therapeutics has released the first clinical batch of its off-the-shelf cell therapy ALA-101 and activated its inaugural trial site at The Alfred, setting the stage for patient dosing later this month.
Ada Torres
Ada Torres
7 Sept 2026
Actinogen Medical (ASX:ACW) has clarified that no undisclosed information explains recent unusual trading in its shares, pointing instead to recent underwriting of options and published updates. The biotech also reaffirmed compliance with ASX rules and provided a detailed update on its lead Alzheimer’s drug Xanamem and ongoing clinical trials.
Ada Torres
Ada Torres
4 Sept 2026
Cleo Diagnostics has received its first commercial batch of ovarian cancer test kits from Bio-Techne, marking the start of analytical validation critical for its FDA submission planned in early 2027.
Ada Torres
Ada Torres
3 Sept 2026
EMVision is progressing its CRC-P funded Regional Benefits Study to evaluate the emu™ bedside brain scanner in remote hospitals, aiming to speed up stroke diagnosis where CT access is limited. Site visits are complete, and protocol development is underway, with relevance extending to similar rural hospitals in the US.
Ada Torres
Ada Torres
3 Sept 2026
AdAlta’s partner SHcell has gained regulatory approval to provide the BZDS1901 CAR-T therapy to advanced mesothelioma patients in China’s Hainan Boao Lecheng special access zone, marking a key milestone in real-world data collection and treatment availability.
Ada Torres
Ada Torres
2 Sept 2026
Telix Pharmaceuticals has completed enrollment in its pivotal Phase 3 BiPASS trial for prostate cancer imaging and aligned with the FDA on a pathway that could expand U.S. patient access and reimbursement for its 68Ga-PSMA-PET agents.
Ada Torres
Ada Torres
2 Sept 2026
Nexalis Therapeutics reports a 52% rise in half-year losses to $1.3 million amid funding facility cancellation and clinical trial suspensions, highlighting ongoing cash flow challenges.
Ada Torres
Ada Torres
1 Sept 2026
Actinogen Medical has locked in full underwriting for nearly 127 million unlisted options, guaranteeing $4.77 million in fresh funding as it approaches pivotal Alzheimer’s trial results due in November.
Ada Torres
Ada Torres
1 Sept 2026

Browse the archive

Full archive